This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Madrid, A. H. Articles by Moro, C. Search for Related Content PubMed PubMed Citation Articles by Madrid, A. H. Articles by Moro, C.

CLINICAL STUDY: ELECTROPHYSIOLOGY

Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study

^a Arrhythmia Unit, Cardiology Department, Ramón y Cajal Hospital, Alcalá University, Department of Medicine, Madrid, Spain

Manuscript received November 16, 1999; revised manuscript received September 5, 2000, accepted October 26, 2000.

Reprint requests and correspondence: Concepción Moro, Unidad de Arritmias, Hospital Ramón y Cajal, Carretera Colmenar Viejo Km. 9, 100, 28034 Madrid, Spain
cmoro{at}hrc.insalud.es

OBJECTIVES

This study was designed to evaluate the efficacy of atenolol for the long-term management of patients with vasovagal syncope. The primary hypothesis was that atenolol is not superior to placebo for the treatment of vasovagal syncope.

BACKGROUND

There is no definitive well-controlled analysis of the efficacy of beta-adrenergic blocking agents in patients with recurrent vasovagal syncope.

METHODS

This is a prospective, randomized, double-blind, placebo-controlled study. Fifty patients with recurrent vasovagal syncope were included (at least two episodes in the last year). A baseline tilt test was performed. Twenty patients (40%) had a positive tilt test. Intravenous atenolol prevented a second positive tilt in five patients. The patients were randomized to receive either atenolol or a placebo (26 patients atenolol 50 mg/day, 24 patients placebo). The follow-up procedure lasted one year. The primary end point of the study was the time to first recurrence of syncope.

RESULTS

In the intention-to-treat analysis, the group treated with atenolol had a similar number of patients with recurrent syncopal episodes as the placebo group. The Kaplan-Meier actuarial estimates of time to first syncopal recurrence showed that the probability of remaining free of syncope drops similarly in both groups and that there was no statistical difference between both curves (patients treated with atenolol vs. the placebo) with a log-rank test p value of 0.4517.

CONCLUSIONS

The recurrence of neurocardiogenic syncope in highly symptomatic patients treated with atenolol is similar to that of patients treated with placebo.

This article has been cited by other articles:

				M. P. Tan and S. W. Parry Reply. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2372 - 2373. [Full Text] [PDF]

				M. P. Tan and S. W. Parry Vasovagal syncope in the older patient. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 599 - 606. [Abstract] [Full Text] [PDF]

				The Steering Committee of the ISSUE 3 Study International study on syncope of uncertain aetiology 3 (ISSUE 3): pacemaker therapy for patients with asystolic neurally-mediated syncope: rationale and study design Europace, January 1, 2007; 9(1): 25 - 30. [Abstract] [Full Text] [PDF]

				M. Brignole and R. Sutton Pacing for neurally mediated syncope: is placebo powerless? Europace, January 1, 2007; 9(1): 31 - 33. [Abstract] [Full Text] [PDF]

				M. Brignole Diagnosis and treatment of syncope Heart, January 1, 2007; 93(1): 130 - 136. [Full Text] [PDF]

				N. van Dijk, F. Quartieri, J.-J. Blanc, R. Garcia-Civera, M. Brignole, A. Moya, W. Wieling, and on behalf of the PC-Trial Investigators Effectiveness of Physical Counterpressure Maneuvers in Preventing Vasovagal Syncope: The Physical Counterpressure Manoeuvres Trial (PC-Trial) J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1652 - 1657. [Abstract] [Full Text] [PDF]

				C. Schroeder, A. L. Birkenfeld, A. F. Mayer, J. Tank, A. Diedrich, F. C. Luft, and J. Jordan Norepinephrine Transporter Inhibition Prevents Tilt-Induced Pre-Syncope J. Am. Coll. Cardiol., August 1, 2006; 48(3): 516 - 522. [Abstract] [Full Text] [PDF]

				M. Brignole, R. Sutton, C. Menozzi, R. Garcia-Civera, A. Moya, W. Wieling, D. Andresen, D. G. Benditt, P. Vardas, and for the International Study on Syncope of Uncertai Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope Eur. Heart J., May 1, 2006; 27(9): 1085 - 1092. [Abstract] [Full Text] [PDF]

				A. P Fitzpatrick and P. Cooper Diagnosis and management of patients with blackouts. Heart, April 1, 2006; 92(4): 559 - 568. [Full Text] [PDF]

				R. Sheldon, S. Connolly, S. Rose, T. Klingenheben, A. Krahn, C. Morillo, M. Talajic, T. Ku, F. Fouad-Tarazi, D. Ritchie, et al. Prevention of Syncope Trial (POST): A Randomized, Placebo-Controlled Study of Metoprolol in the Prevention of Vasovagal Syncope Circulation, March 7, 2006; 113(9): 1164 - 1170. [Abstract] [Full Text] [PDF]

				G. N. Theodorakis, D. Leftheriotis, E. G. Livanis, P. Flevari, G. Karabela, N. Aggelopoulou, and D. Th. Kremastinos Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace, March 1, 2006; 8(3): 193 - 198. [Abstract] [Full Text] [PDF]

				B. P. Grubb Neurocardiogenic Syncope N. Engl. J. Med., March 10, 2005; 352(10): 1004 - 1010. [Full Text] [PDF]

				M. A. Salim and T. G. Di Sessa Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children: A double-blind, placebo-controlled, randomized trial J. Am. Coll. Cardiol., February 15, 2005; 45(4): 484 - 488. [Abstract] [Full Text] [PDF]

				A. Raviele, F. Giada, C. Menozzi, G. Speca, S. Orazi, G. Gasparini, R. Sutton, M. Brignole, and for the Vasovagal Syncope and Pacing Trial Investi A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE) Eur. Heart J., October 1, 2004; 25(19): 1741 - 1748. [Abstract] [Full Text] [PDF]

				Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF]

				G. Foglia-Manzillo, F. Giada, G. Gaggioli, A. Bartoletti, G. Lolli, M. Dinelli, A. Del Rosso, M. Santarone, A. Raviele, and M. Brignole Efficacy of tilt training in the treatment of neurally mediated syncope. A randomized study Europace, January 1, 2004; 6(3): 199 - 204. [Abstract] [Full Text] [PDF]

				F. Croci, M. Brignole, C. Menozzi, A. Solano, P. Donateo, D. Oddone, E. Puggioni, and G. Lolli Efficacy and feasibility of isometric arm counter-pressure manoeuvres to abort impending vasovagal syncope during real life Europace, January 1, 2004; 6(4): 287 - 291. [Abstract] [Full Text] [PDF]

				Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology Europace, January 1, 2004; 6(6): 467 - 537. [Full Text] [PDF]

				W. N. Kapoor Is There an Effective Treatment for Neurally Mediated Syncope? JAMA, May 7, 2003; 289(17): 2272 - 2275. [Full Text] [PDF]

				R. Sheldon, S. Rose, S. Connolly, and on behalf of the POST investigators Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope: Rationale and study design Europace, January 1, 2003; 5(1): 71 - 75. [Abstract] [PDF]

				W. N. Kapoor Current Evaluation and Management of Syncope Circulation, September 24, 2002; 106(13): 1606 - 1609. [Full Text] [PDF]

				P. Flevari, E. G. Livanis, G. N. Theodorakis, E. Zarvalis, T. Mesiskli, and D. T. h Kremastinos Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being J. Am. Coll. Cardiol., August 7, 2002; 40(3): 499 - 504. [Abstract] [Full Text] [PDF]

				G Baron-Esquivias, A Pedrote, A Cayuela, J.I Valle, J.M Fernandez, E Arana, M Fernandez, F Morales, J Burgos, and A Martinez-Rubio Long-term outcome of patients with asystole induced by head-up tilt test Eur. Heart J., March 2, 2002; 23(6): 483 - 489. [Abstract] [Full Text] [PDF]

				R. S. Sheldon, S. R. Raj, S. Rose, and S. J. Connolly Beta-blockers in syncope: the jury is still out J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2135 - 2135. [Full Text] [PDF]

				C. Moro and A. H. Madrid Beta-blockers in syncope: the jury is still out: Reply J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2135 - 2136. [Full Text] [PDF]

				Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al. Guidelines on management (diagnosis and treatment) of syncope Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306. [Abstract] [PDF]

				Are Beta-Blockers Effective for Neurally Mediated Syncope? Journal Watch Cardiology, April 6, 2001; 2001(406): 8 - 8. [Full Text]

				J. S. Sra Can we assess the efficacy of therapy in neurocardiogenic syncope? J. Am. Coll. Cardiol., February 1, 2001; 37(2): 560 - 561. [Full Text] [PDF]

				R. Sheldon and S. Rose Components of clinical trials for vasovagal syncope Europace, January 1, 2001; 3(3): 233 - 240. [Abstract] [PDF]